RNXT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RenovoRx Inc (RNXT) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 to invest. The technical indicators are bearish, there are no significant trading signals, and while the company has promising technology and a positive analyst rating, its financial performance and lack of immediate catalysts do not support a strong buy recommendation.
The technical indicators for RNXT are bearish. The MACD is negatively expanding, the RSI is neutral at 22.279, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 0.92 and resistance at 1.057.
The company has an FDA-cleared device, RenovoCath, which is seen as particularly useful for treating pancreatic cancer. An analyst has initiated coverage with a Buy rating and an $8 price target, indicating potential long-term growth.
The stock has no recent news, no significant trading trends from hedge funds or insiders, and no recent congressional trading data. Additionally, the financials show a significant YoY drop in EPS (-60%) and gross margin (-11.76%).
In Q4 2025, revenue increased by 453.49% YoY to $238,000, and net income improved slightly by 2.19% YoY to -$2,941,000. However, EPS dropped significantly (-60% YoY), and gross margin decreased to 88.24%, down 11.76% YoY.
JonesResearch analyst Justin Walsh initiated coverage with a Buy rating and an $8 price target. The analyst views the company's technology as promising, particularly for pancreatic cancer treatment.
